Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estrogen-induced pancreatitis.

W A Parker

    Clinical Pharmacy
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Increase of Lunacy.

    Glasgow medical journal·2018
    Same author

    Canadian Drug Products Containing ASA.

    Canadian family physician Medecin de famille canadien·2011
    Same author

    Clinical pharmacology of sodium salicylate.

    The Quarterly journal of medicine·2010
    Same author

    Experiences with extended-duration medical laboratory support in deployable medical systems.

    Military medicine·1996
    Same author

    Imaging of HDR brachytherapy dose distributions using NMR Fricke-gelatin dosimetry.

    Magnetic resonance imaging·1994
    Same author

    Ethnicity, location, age, and fluoridation factors in baby bottle tooth decay and caries prevalence of Head Start children.

    Public health reports (Washington, D.C. : 1974)·1992
    Same journal

    Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

    Clinical pharmacy·1993
    Same journal

    Accuracy of unbound-quinidine concentration determination after ultrafiltration.

    Clinical pharmacy·1993
    Same journal

    Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

    Clinical pharmacy·1993
    Same journal

    Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

    Clinical pharmacy·1993
    Same journal

    Efficacy of nutritional supplements used by athletes.

    Clinical pharmacy·1993
    Same journal

    Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

    Clinical pharmacy·1993
    See all related articles

    Oral contraceptives containing estrogen can induce hyperlipidemia, leading to acute pancreatitis. This case highlights the importance of monitoring lipid levels in patients using oral contraceptives.

    Area of Science:

    • Endocrinology
    • Gastroenterology
    • Pharmacology

    Background:

    • Oral contraceptive therapy is widely used for birth control.
    • Hyperlipidemia is a known potential side effect of estrogen administration.
    • Acute pancreatitis is a serious inflammatory condition of the pancreas.

    Observation:

    • A 23-year-old woman experienced recurrent acute pancreatitis episodes temporally associated with oral contraceptive use.
    • Laboratory findings included elevated blood glucose, amylase, cholesterol, and triglycerides, with a type IV lipoprotein pattern.
    • Abdominal sonogram showed a normal pancreas.

    Findings:

    • The patient's acute pancreatitis was diagnosed as secondary to oral-contraceptive-induced hyperlipidemia.
    • Discontinuation of oral contraceptive therapy led to symptom resolution and normalization of lipid levels.
    Keywords:
    BiologyCase HistoriesContraceptionContraceptive AgentsContraceptive Agents, FemaleContraceptive Methods--side effectsData CollectionEndocrine SystemEstrogens--side effectsFamily PlanningHormonesLaboratory ProceduresLipid Metabolic Effects--analysisLipidsOral Contraceptives--side effectsPhysiologyReproductive Control AgentsResearch MethodologyTreatment

    Related Experiment Videos

  • Estrogen therapy is implicated in causing hyperlipemia and subsequent pancreatitis.

    • Implications:

    • Monitoring serum lipid concentrations before and during estrogen therapy is recommended.
    • Patients over 40 or with a family history of hyperlipemia are at increased risk.
    • Estrogen therapy should be discontinued if pancreatitis occurs.